The five-year survival rate after surgery of ovarian cancer patients with positive expression of BMP-2, BMPRIB, and BMPRII was remarkably higher than that of patients with negative expression of BMP-2, BMPRIB, and BMPRII. This evidence concerns the gene BMP2 and ovarian carcinoma.